Amer Zeidan MBBS,MHS ‏عامر زيدان (@dr_amerzeidan) 's Twitter Profile
Amer Zeidan MBBS,MHS ‏عامر زيدان

@dr_amerzeidan

#Leukemia doctor focusing on #MDSsm & #AMLsm. Personal/own opinions. COI bit.ly/2YfwJ9V

ID: 1144997352148787201

calendar_today29-06-2019 15:53:36

15,15K Tweet

23,23K Followers

236 Following

Yale Cancer Center (@yalecancer) 's Twitter Profile Photo

A new study with Jennifer Kwan MD PhD showed insights into the association between #cardiotoxicity in CAR T-cell therapy + the levels of brain natriuretic peptide (BNP), C-reactive protein (CRP), creatinine, and ferritin, and highlights specific biomarker trends in CAR T-cell

Samuele Ferrari (@ferrari_sam93) 's Twitter Profile Photo

I am thrilled to announce that I have been selected by ASH to receive the 2024 ASH Global Research Award! #ASHAwards So excited to explore new avenues and deeply thankful for the outstanding support from my institution and mentors!

I am thrilled to announce that I have been selected by <a href="/ASH_hematology/">ASH</a> to receive the 2024 ASH Global Research Award! #ASHAwards

So excited to explore new avenues and deeply thankful for the outstanding support from my institution and mentors!
Marion E Mass, M.D. #patientsfirst #scrubsnotsuits (@mass_marion) 's Twitter Profile Photo

“Why are EHR systems so primitive? Partly because vendors must be certified as compliant by the Department of Health and Human Services, inhibiting better products and insulating existing ones from best-in-tech competitive pressures.” From 2018 The Wall Street Journal with Dr Ken Fisher While

“Why are EHR systems so primitive? Partly because vendors must be certified as compliant by the Department of Health and Human Services, inhibiting better products and insulating existing ones from best-in-tech competitive pressures.”
From 2018 <a href="/WSJ/">The Wall Street Journal</a> with Dr Ken Fisher 
While
Blood Cancers Today (@blood_cancers) 's Twitter Profile Photo

After a string of robust clinical trial data, patients with low-risk #MDS now have two newly approved treatment options: luspatercept and imetelstat. Check out our latest feature with insight from Somedeb Ball, Amer Zeidan MBBS,MHS ‏عامر زيدان, Srinivas Tantravahi, and more. 📰 buff.ly/3MnRcSg

After a string of robust clinical trial data, patients with low-risk #MDS now have two newly approved treatment options: luspatercept and imetelstat.

Check out our latest feature with insight from <a href="/drsomedeb/">Somedeb Ball</a>, <a href="/Dr_AmerZeidan/">Amer Zeidan MBBS,MHS ‏عامر زيدان</a>, <a href="/sk_tantravahi/">Srinivas Tantravahi</a>, and more.

📰 buff.ly/3MnRcSg
Amer Zeidan MBBS,MHS ‏عامر زيدان (@dr_amerzeidan) 's Twitter Profile Photo

Please join me in voting for the one and only Mikkael A. Sekeres MD, MS as the next ASH secretary at vote.escvote.com/ash I have now know Mikkael for almost 15 years and he has been always a very thoughtful & caring physician, an excellent researcher, passionate advocate for

Chris Hourigan (@drchrishourigan) 's Twitter Profile Photo

Faculty opening!!! Come build your cancer research program with us at the new Virginia Tech Fralin Biomedical Research Institute Cancer Research Center in Washington, DC. fbri.vt.edu/dc Brand new laboratory space in a research-focused institute based five miles from

Faculty opening!!! Come build your cancer research program with us at the new Virginia Tech Fralin Biomedical Research Institute Cancer Research Center in Washington, DC.  fbri.vt.edu/dc   Brand new laboratory space in a research-focused institute based five miles from
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

🎉 Huge congratulations to Hatice Bölek a rising star in oncology, for her remarkable work on our latest study in JCO Global Oncology! While many mRCC/mBC patients remain optimistic, this often leads to inaccurate cure beliefs. Enhancing communication about prognosis is crucial

🎉 Huge congratulations to <a href="/hatice_bolek/">Hatice Bölek</a> a rising star in oncology, for her remarkable work on our latest study in JCO Global Oncology! 
While many mRCC/mBC patients remain optimistic, this often leads to inaccurate cure beliefs. Enhancing communication about prognosis is crucial
Yale Hematology Oncology Fellows (@yalehemonc) 's Twitter Profile Photo

It is not quite 2 months since our first year fellows started fellowship and what a brilliant group it is. Case and point is Dr. Casasanta who excelled on one of our toughest services, hematology consults with her attending stating "Nicole is a rockstar." Oh we know 💫🤟!

It is not quite 2 months since our first year fellows started fellowship and what a brilliant group it is. Case and point is Dr. Casasanta who excelled on one of our toughest services, hematology consults with her attending stating "Nicole is a rockstar." Oh we know 💫🤟!
Blood Cancers Today (@blood_cancers) 's Twitter Profile Photo

🙌 ICYMI: Amer Zeidan MBBS,MHS ‏عامر زيدان, of Yale Cancer Center, discusses the state of lower-risk #MDS. 🗨️ "We moved from not having really any important options to treat patients to having multiple drugs,” he said. 📺 Watch the full interview: buff.ly/3X3zSHe

🙌 ICYMI: <a href="/Dr_AmerZeidan/">Amer Zeidan MBBS,MHS ‏عامر زيدان</a>, of <a href="/YaleCancer/">Yale Cancer Center</a>, discusses the state of lower-risk #MDS.

🗨️ "We moved from not having really any important options to treat patients to having multiple drugs,” he said.

📺 Watch the full interview: buff.ly/3X3zSHe